CNMD CONMED CorpcompanySEC Filings & Insider Trading Activity 2026
Latest CONMED Corp (CNMD) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 17, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on April 29, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for CONMED Corp (CNMD) (SEC CIK 816956), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model centered on medical industry products and services, emphasizing talent attraction and retention amid intense competition
- • Suspension of quarterly dividend payments since October 2025 to extend share repurchase program, with future dividends uncertain due to financial and legal constraints
Risk Factors
- • Financial risk $840M long-term debt with $800M convertible notes due 2027 requiring incremental financing
- • Operational risk increased capital spending expected in 2026 funded by operating cash flow with monitored control
Management Discussion & Analysis
- • Revenue $555M, flat YoY with orthopedic surgery and general surgery stable at 42% and 58% of sales respectively
- • Gross margin 48.3% vs 49.1% in prior year, reflecting inflationary cost pressures and supply chain challenges
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • CFO role vacant — Andrew Moller named Interim Principal Financial Officer effective March 15, 2026, signaling unplanned departure of prior CFO
- • Moller is an internal promotion from VP Corporate Controller/Principal Accounting Officer, a role he held only since April 2025
Annual Reports Archive10-K
AI-powered analysis of CONMED Corp (CNMD) 10-K annual reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of CONMED Corp (CNMD) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $1.0B | $1.2B | $1.3B | $1.4B |
| Gross Profit | $571.2M | $676.2M | $733.0M | $750.5M |
| Operating Income | — | $120.6M | $200.3M | $102.6M |
| Net Income | — | $64.5M | $132.4M | $47.1M |
| Gross Margin | 54.6% | 54.3% | 56.1% | 54.6% |
| Op. Margin | — | 9.7% | 15.3% | 7.5% |
| Net Margin | — | 5.2% | 10.1% | 3.4% |
| Balance Sheet | ||||
| Total Assets | — | $2.3B | $2.3B | $2.3B |
| Equity | — | $834.2M | $962.7M | $1.0B |
| ROE | — | 7.7% | 13.8% | 4.6% |
Source: XBRL financial data from CONMED Corp (CNMD) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 29, 2026 | — | — | — |
8-K | Mar 13, 2026 | — | Analysis | — |
10-K | Feb 17, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 28, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Jan 8, 2026 | — | — | |
8-K | Dec 5, 2025 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | — | |
10-Q | Jul 31, 2025 | Jun 30, 2025 | — | |
10-Q | May 1, 2025 | Mar 31, 2025 | — | |
10-K | Feb 18, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 25, 2024 | Mar 31, 2024 | — | |
10-K | Feb 28, 2024 | Dec 31, 2023 | — | |
10-Q | Oct 26, 2023 | Sep 30, 2023 | — | |
10-Q | Jul 27, 2023 | Jun 30, 2023 | — | |
10-Q | Apr 27, 2023 | Mar 31, 2023 | — | |
10-K | Feb 21, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 27, 2022 | Sep 30, 2022 | — | |
10-Q | Jul 28, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 22, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 28, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 29, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest CNMD SEC filings in 2026?
CONMED Corp (CNMD) has filed a 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on April 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did CNMD file its most recent 10-K annual report?
CONMED Corp (CNMD) filed its most recent 10-K annual report on February 17, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view CNMD 10-Q quarterly reports?
CONMED Corp (CNMD)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every CNMD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has CNMD filed recently?
CONMED Corp (CNMD)'s most recent 8-K was filed on April 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find CNMD insider trading activity (Form 4)?
SignalX aggregates every CNMD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does CNMD file with the SEC?
CONMED Corp (CNMD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CNMD filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for CONMED Corp (CNMD).
What is CNMD's SEC CIK number?
CONMED Corp (CNMD)'s SEC CIK (Central Index Key) number is 816956. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 816956 to look up all CNMD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find CNMD return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from CONMED Corp (CNMD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of CONMED Corp SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 50+ filings.